MovDisordV3, Main, Exploration, bibRecordById, Pascal:97-0142930

A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism

Identifieur interne : 005425 ( Main/Exploration ); précédent : 005424; suivant : 005426

A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism

Auteurs : A. Negrotti [Italie] ; Calzetti [Italie]

Source :

Movement Disorders [ 0885-3185 ] ; 1997-01.

RBID : ISTEX:B76868CF03D01070A891C66A47A9A4CDFAF31704

Descripteurs français

Pascal (Inist)
- Antagoniste, Antagoniste calcium, Antiallergique, Anticonvulsivant, Antihistaminique, Antiémétique, Cinnarizine, Etude longitudinale, Flunarizine, Long terme, Parkinsonisme, Pipérazine dérivé, Pronostic, Récepteur histaminergique H1, Toxicité, Vasodilatateur, Vieillard.

English descriptors

KwdEn :
- Aged, Antagonist, Antiallergic, Anticonvulsant, Antiemetic, Antihistaminic, Calcium Channel Blockers (administration & dosage), Calcium Channel Blockers (adverse effects), Calcium antagonist, Cardiovascular Diseases (drug therapy), Cinnarizine, Cinnarizine (administration & dosage), Cinnarizine (adverse effects), Dose-Response Relationship, Drug, Drug‐induced, Elderly, Female, Flunarizine, Flunarizine (administration & dosage), Flunarizine (adverse effects), Follow up study, Follow-Up Studies, H1 receptor, Humans, Long term, Long‐term outcome, Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinsonism, Piperazine derivatives, Prognosis, Toxicity, Treatment Outcome, Vasodilator agent.
MESH :
- chemical , administration & dosage : Calcium Channel Blockers, Cinnarizine, Flunarizine.
- chemical , adverse effects : Calcium Channel Blockers, Cinnarizine, Flunarizine.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary.
- drug effects : Neurologic Examination.
- drug therapy : Cardiovascular Diseases.
- Aged, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.

Abstract

The natural course of calcium‐entry blocker–induced parkinsonism was evaluated in 13 elderly patients previously exposed to cinnarizine or flunarizine or both for a median period of 7 months. Clinical assessments were carried out before drug discontinuation and twice thereafter over a period lasting ≤7 years. None of the patients showed a full recovery of extrapyramidal signs, indicating that the long‐term prognosis of the parkinsonism is less benign than previously reported. Two main patterns of clinical outcome were recognized (i.e., “remittent” and “persistent and not progressive”parkinsonism), whereas the development of a progressive disorder was observed only in one patient. No significant correlation was found between the patterns of outcome and some clinical variables, such as total duration of exposure to cinnarizine and flunarizine, cumulative drug dosages, and age at onset of parkinsonism. There was no significant difference in terms of family history of essential tremor or parkinsonism or both among the patients with the two main patterns of clinical course.

Url:

https://api.istex.fr/document/B76868CF03D01070A891C66A47A9A4CDFAF31704/fulltext/pdf

DOI: 10.1002/mds.870120119

Affiliations:

Italie

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism</title>
<author><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
</author>
<author><name sortKey="Calzetti" sort="Calzetti" uniqKey="Calzetti" last="Calzetti">Calzetti</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B76868CF03D01070A891C66A47A9A4CDFAF31704</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/mds.870120119</idno>
<idno type="url">https://api.istex.fr/document/B76868CF03D01070A891C66A47A9A4CDFAF31704/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D67</idno>
<idno type="wicri:Area/Istex/Curation">002D67</idno>
<idno type="wicri:Area/Istex/Checkpoint">003A49</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Negrotti A:a:long:term</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8990063</idno>
<idno type="wicri:Area/PubMed/Corpus">004723</idno>
<idno type="wicri:Area/PubMed/Curation">004723</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004730</idno>
<idno type="wicri:Area/Ncbi/Merge">004C60</idno>
<idno type="wicri:Area/Ncbi/Curation">004C60</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C60</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Negrotti A:a:long:term</idno>
<idno type="wicri:Area/Main/Merge">008454</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:97-0142930</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003292</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003532</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003291</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Negrotti A:a:long:term</idno>
<idno type="wicri:Area/Main/Merge">008646</idno>
<idno type="wicri:Area/Main/Curation">005425</idno>
<idno type="wicri:Area/Main/Exploration">005425</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism</title>
<author><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Istituto di Neurologia, Università di Parma, Parma</wicri:regionArea>
<wicri:noRegion>Parma</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calzetti" sort="Calzetti" uniqKey="Calzetti" last="Calzetti">Calzetti</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Istituto di Neurologia, Università di Parma, Parma</wicri:regionArea>
<wicri:noRegion>Parma</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-01">1997-01</date>
<biblScope unit="vol">12</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="107">107</biblScope>
<biblScope unit="page" to="110">110</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B76868CF03D01070A891C66A47A9A4CDFAF31704</idno>
<idno type="DOI">10.1002/mds.870120119</idno>
<idno type="ArticleID">MDS870120119</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antagonist</term>
<term>Antiallergic</term>
<term>Anticonvulsant</term>
<term>Antiemetic</term>
<term>Antihistaminic</term>
<term>Calcium Channel Blockers (administration & dosage)</term>
<term>Calcium Channel Blockers (adverse effects)</term>
<term>Calcium antagonist</term>
<term>Cardiovascular Diseases (drug therapy)</term>
<term>Cinnarizine</term>
<term>Cinnarizine (administration & dosage)</term>
<term>Cinnarizine (adverse effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug‐induced</term>
<term>Elderly</term>
<term>Female</term>
<term>Flunarizine</term>
<term>Flunarizine (administration & dosage)</term>
<term>Flunarizine (adverse effects)</term>
<term>Follow up study</term>
<term>Follow-Up Studies</term>
<term>H1 receptor</term>
<term>Humans</term>
<term>Long term</term>
<term>Long‐term outcome</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (diagnosis)</term>
<term>Parkinsonism</term>
<term>Piperazine derivatives</term>
<term>Prognosis</term>
<term>Toxicity</term>
<term>Treatment Outcome</term>
<term>Vasodilator agent</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Cinnarizine</term>
<term>Flunarizine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Cinnarizine</term>
<term>Flunarizine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term>
<term>Antagoniste calcium</term>
<term>Antiallergique</term>
<term>Anticonvulsivant</term>
<term>Antihistaminique</term>
<term>Antiémétique</term>
<term>Cinnarizine</term>
<term>Etude longitudinale</term>
<term>Flunarizine</term>
<term>Long terme</term>
<term>Parkinsonisme</term>
<term>Pipérazine dérivé</term>
<term>Pronostic</term>
<term>Récepteur histaminergique H1</term>
<term>Toxicité</term>
<term>Vasodilatateur</term>
<term>Vieillard</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The natural course of calcium‐entry blocker–induced parkinsonism was evaluated in 13 elderly patients previously exposed to cinnarizine or flunarizine or both for a median period of 7 months. Clinical assessments were carried out before drug discontinuation and twice thereafter over a period lasting ≤7 years. None of the patients showed a full recovery of extrapyramidal signs, indicating that the long‐term prognosis of the parkinsonism is less benign than previously reported. Two main patterns of clinical outcome were recognized (i.e., “remittent” and “persistent and not progressive”parkinsonism), whereas the development of a progressive disorder was observed only in one patient. No significant correlation was found between the patterns of outcome and some clinical variables, such as total duration of exposure to cinnarizine and flunarizine, cumulative drug dosages, and age at onset of parkinsonism. There was no significant difference in terms of family history of essential tremor or parkinsonism or both among the patients with the two main patterns of clinical course.</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
</noRegion>
<name sortKey="Calzetti" sort="Calzetti" uniqKey="Calzetti" last="Calzetti">Calzetti</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005425 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005425 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B76868CF03D01070A891C66A47A9A4CDFAF31704
   |texte=   A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism

A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.